tirzepatide pastillas precio en méxico Aprobada la tirzepatida, un nuevo medicamento para reducir peso, que llegará en junio de 2025 Un tratamiento innovador para la obesidad recibe autorización oficial y se espera su comercialización en En BM Farma tenemos medicamentos

Nakamura Regulatory Affairs Lead, APAC

For those at increased cardiovascular risk, the aim is typically to achieve at least a 40% reduction in non-HDL cholesterol with appropriate statin therapy, rather than targeting specific threshold values

What started as a glucose-control challenge is now driving innovation across: Obesity Medicine Cardiovascular Care Kidney Disease AI-Powered Healthcare Precision Medicine A few trends reshaping the landscape: Diabetes is projected to affect 783 million people by 2045

the different composition of the gut microbiota compared to patients with obesity (188)

[4] [2] Clinical observations suggest the hair loss typically manifests as telogen effluvium a form of diffuse hair shedding that occurs when a significant number of hair follicles enter the resting (telogen) phase prematurely